Fig. 6From: A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progressionThe effect of other key drugs for DLBCL therapy on BTK and pan-PIM inhibitors. (a) Venetoclax (0.1 μM) showed the most synergistic effect on Ibrutinib (10 μM)- and AZD 1208 (40 μM)-induced apoptosis (p < 0.01). (b) These drugs did not significantly decrease the BCL2 levels, although some of them exerted notable inhibitory on BCL-XL and MCL1 levelsBack to article page